TRKA (G595R/L657M)
Sign in to save this workspaceNTRK1 · Variant type: compound · HGVS: p.G595R;p.L657M
Components
p.G595Rp.L657M
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Repotrectinib | 96.0% | 4.0% | 84.21 |
| 2 | Ponatinib | 94.7% | 5.3% | 78.23 |
| 3 | Cabozantinib | 69.4% | 30.6% | 92.73 |
| 4 | Darovasertib | 58.1% | 41.9% | 96.99 |
| 5 | Tivozanib | 51.0% | 49.0% | 92.42 |
| 6 | Ripretinib | 26.8% | 73.2% | 92.95 |
| 7 | Defactinib | 19.8% | 80.2% | 92.68 |
| 8 | Pralsetinib | 10.4% | 89.6% | 93.43 |
| 9 | Brigatinib | 10.0% | 90.0% | 82.96 |
| 10 | Lorlatinib | 9.4% | 90.6% | 97.24 |
| 11 | Avapritinib | 9.4% | 90.6% | 97.73 |
| 12 | Zanubrutinib | 7.1% | 92.9% | 98.24 |
| 13 | Abrocitinib | 6.5% | 93.5% | 99.50 |
| 14 | Sorafenib | 6.3% | 93.7% | 96.72 |
| 15 | Tepotinib | 6.2% | 93.8% | 99.75 |
| 16 | Mitapivat | 6.0% | 94.0% | 100.00 |
| 17 | Vemurafenib | 5.8% | 94.2% | 96.49 |
| 18 | Upadacitinib | 5.6% | 94.4% | 97.98 |
| 19 | Tucatinib | 5.0% | 95.0% | 99.75 |
| 20 | Neratinib | 4.8% | 95.2% | 93.18 |
| 21 | Erdafitinib | 4.5% | 95.5% | 95.71 |
| 22 | Idelalisib | 4.3% | 95.7% | 100.00 |
| 23 | Pazopanib | 4.0% | 96.0% | 97.49 |
| 24 | Selumetinib | 4.0% | 96.0% | 100.00 |
| 25 | Ribociclib | 3.7% | 96.3% | 99.25 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Repotrectinib | 96.0% | 98.9% | -2.9% |
| Ponatinib | 94.7% | 98.4% | -3.6% |
| Cabozantinib | 69.4% | 93.6% | -24.2% |
| Darovasertib | 58.1% | — | — |
| Tivozanib | 51.0% | 85.7% | -34.6% |
| Ripretinib | 26.8% | 93.6% | -66.8% |
| Defactinib | 19.8% | 80.3% | -60.5% |
| Pralsetinib | 10.4% | 98.7% | -88.3% |
| Brigatinib | 10.0% | — | — |
| Lorlatinib | 9.4% | 63.2% | -53.9% |
| Avapritinib | 9.4% | — | — |
| Zanubrutinib | 7.1% | — | — |
| Abrocitinib | 6.5% | — | — |
| Sorafenib | 6.3% | — | — |
| Tepotinib | 6.2% | — | — |
| Mitapivat | 6.0% | — | — |
| Vemurafenib | 5.8% | — | — |
| Upadacitinib | 5.6% | — | — |
| Tucatinib | 5.0% | — | — |
| Neratinib | 4.8% | — | — |
| Erdafitinib | 4.5% | — | — |
| Idelalisib | 4.3% | — | — |
| Pazopanib | 4.0% | — | — |
| Selumetinib | 4.0% | — | — |
| Ribociclib | 3.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.1ms